Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 déc. 2025 08h05 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Sangamo Therapeutics today announced that the FDA has granted Fast Track Designation to ST-503 in chronic neuropathic pain
21 nov. 2025 08h05 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

U.S. FDA has accepted Sangamo’s request for a rolling submission and review of the BLA for ST-920 in Fabry disease
06 nov. 2025 08h01 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2025 FINANCIAL RESULTS
30 oct. 2025 16h01 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 EARNINGS CALL
04 sept. 2025 08h05 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM 2025
07 août 2025 16h01 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics reports recent business highlights and second quarter 2025 financial results
31 juil. 2025 16h05 HE | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second...
18 nov. 2014 16h02 HE | Source: Sangamo Therapeutics, Inc.

Sangamo BioSciences Announces Presentation at the 26th Annual Piper Jaffray Healthcare Conference

RICHMOND, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of...